Patient centricity is a key priority for today’s pharmaceutical industry. The profound shift of meeting the expectations of ever better informed and more involved patients and caregivers also concerns and business-to-business (B2B) partners of the pharmaceutical industry.
Patient centricity presents challenges and ample opportunities for value generation for B2B partners along the pharmaceutical value chain.
Following the approach of simply listening to and observing patients in their use of transdermal therapeutic systems (TTS), LTS has ventured into the previously unknown. Namely, how do patients actually use and perceive transdermal delivery systems (TTS)?
Applying state-of-the-art consumer research in a patient study in Germany, LTS has systematically assessed patient requirements and appreciation of transdermal delivery systems versus conventional administration routes. Interviewing patients directly, LTS gained valuable insights.
The results of the LTS-sponsored patient study confirmed the decisive patient preference for transdermal delivery in pain indications over alternative forms of administration. The patient feedback also provided valuable insights into how to further improve the patient’s experience.
Besides clinical and therapeutic considerations, the patient’s feedback guides how to further optimise advantageous delivery systems. Corresponding with improved patient experience also value generation and retention for the pharmaceutical industry stands to benefit.
Around 50 patients took part in the study. They were suffering from chronic moderate-to-severe pain and using fentanyl, buprenorphine or lidocaine over a minimum period of five months. They were interviewed by a Munich-based independent market research institute.